World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF TRANSITIONAL CELL CARCINOMA USING SIMILAR MOLECULE - SOTORASIB M24

Dr. Syed Ahmed Hussain*, Raheem Unnisa Shaik, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa and Nazneen

ABSTRACT

Aim: This research aims to evaluate the efficacy of Sotorasib M24, a novel molecule targeting the KRAS gene, in
comparison to the marketed drug Pembrolizumab (Keytruda) for the treatment of Non-Small Cell Lung Cancer
(NSCLC). Objective: The objective is to investigate the cytotoxic effects of these compounds on kidney cancer
cell lines using various cell viability assays, thereby identifying potential alternative therapies for NSCLC patients.
Research: Utilizing MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH cytotoxicity assays, the study measures the
effects of Sotorasib M24 on cell viability at multiple concentrations. The results indicate a significant dosedependent
cytotoxic effect of Sotorasib M24, with viable cell counts decreasing as concentration increases.
Conclusion: The findings suggest that Sotorasib M24 could serve as a promising alternative therapy for NSCLC,
particularly for patients with KRAS mutations. Future studies are needed to confirm these results in clinical
settings and further explore the therapeutic potential of Sotorasib M24 in combination with existing treatments.

[Full Text Article]   [Download Certificate]